Objectives:

- To highlight the unmet medical needs of patients with Parkinson’s disease
- To educate on the importance of early clinical signs of Parkinson’s disease, particularly non-motor manifestations that may manifest many years earlier than motor symptoms
- To communicate the challenges in identifying and measuring non-motor symptoms of Parkinson’s disease in clinical trials and discuss potential novel endpoints
- To educate on the role of aggregated alpha-synuclein in Parkinson’s disease, which is central to Parkinson’s disease pathogenesis

Agenda:

A brief Q&A will be held after each presentation

17.15 – 17.20 Welcome and Introductions
Wolfgang Oertel, MD, PhD

17.20 – 17.35 Early Symptoms of Parkinson’s Disease: The Patient’s Perspective
Tom Isaacs

17.35 – 17.55 Spreading of Protein Aggregates in Animal Models of alpha-Synucleinopathies
Patrik Brundin, MD, PhD

17.55 – 18.15 alpha-Synuclein Pathology in the Peripheral and Central Nervous Systems
Thomas Beach, PhD, MD

18.15 – 18.35 Non-motor Symptoms in Parkinson’s Disease
Brit Mollenhauer, Dr. Med.

18.35 – 18.55 Prodromal Parkinson’s Disease
Ronald Postuma, MD, MSc

18.55 – 19.15 Novel Endpoints for Measuring Non-motor Symptoms in Parkinson’s Disease
Jamie L Eberling, PhD

19.15 Adjournment

Pre-registration is not required; however, it is recommended that you arrive early. Seating is on a first-come, first-served basis.

This symposium is not intended for physicians practicing in the USA.
This symposium is organized by Prothena Biosciences Inc and F. Hoffmann-La Roche Ltd.